Progressive Planet Solutions Inc. (TSXV: PLAN) (“PLAN” or “Progressive Planet”), announces that it has engaged C&CS Atlantic Inc. to complete  testing required to commercially launch PozGlass SCM. The principal of C&CS Atlantic is Dr. Michael Thomas .

In 2020, the University of Alberta conducted an initial set of tests on the company’s Natural Pozzolan Blend, which showed superior qualities to fly ash as a supplementary cementing material. Due to COVID-19, the U of A was only able to complete some of the necessary tests.

The additional testing will be conducted in two phases with phase one expected to be completed by the end of April 2021 and phase two in the third quarter of 2021.

Subject to a successful completion of the additional tests such as compressive strength and alkali-silica reactivity, management will move to a full-scale commercial roll-out of the PozGlass SCM product. PozGlass SCM combines natural pozzolan, recycled, post-consumer glass, and proprietary formulations and processes. The objective is to displace fly ash, a by-product of burning coal for electricity generation, with an environmentally friendly product that creates enhanced properties in ready mix and pre-cast concrete.

Michael Thomas is a Professor in the Department of Civil Engineering at the University of New Brunswick (UNB), Canada , and a registered Professional Engineer in the province of New Brunswick . Michael has been working in the field of cement and concrete research since 1983.

Prior to joining UNB in 2002, Michael had been on faculty at the University of Toronto since 1994, and previous to this, he worked as a concrete materials engineer with Ontario Hydro in Canada (1991-93) and as a research fellow with the Building Research Establishment in the UK (1986-1991).

Dr. Thomas’s main research interests are concrete durability and the use of industrial by-products including pozzolans and slag. Dr. Thomas has authored more than 200 technical papers and reports including the book “Supplementary Cementing Materials in Concrete”.

Dr. Thomas is active on technical committees within the American Concrete Institute (ACI), ASTM, RILEM, and the Canadian Standards Association (Awarded Order of Merit in 2010). He was a recipient of the ACI’s Wason Medal for Materials Research in 1997, 2009 and 2014, the ACI Construction Practice Award in 2001 and was elected to a Fellow of the Institute in 2006.

“PLAN is excited to commence a working relationship with C&CS Atlantic and Dr. Thomas. As we continue to build our team, we are focused on procuring world class talent. We are also proud to use Canadian expertise wherever possible,” stated Steve Harpur , CEO.

In addition to conducting tests on pozzolans owned by PLAN, the testing regimen includes testing additional pozzolans which PLAN is evaluating for potential future use.

ABOUT PROGRESSIVE PLANET

Progressive Planet is an emerging leader in supplying solutions for a livable planet by developing low carbon, pozzolan-based, cementing products which replace equivalent amounts of Portland Cement and fly ash in concrete. The production of Portland Cement is the second largest global generator of CO2 emissions.

Progressive Planet operates its flagship Z1 Zeolite Quarry in British Columbia and is earning an 100% interest in the Z2 Natural Pozzolan Property near Falkland, BC and earning a 100% interest in the Heffley Creek Metals and Natural Pozzolan Property. All three properties are within a one-hour drive of Kamloops, BC , an industrial hub with rail access to Canadian and US markets.

Forward-Looking Statements:
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Progressive Planet Solutions

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2021/25/c5200.html

News Provided by Canada Newswire via QuoteMedia

In the cannabis space this week, retailer Fire & Flower Holdings (TSX:FAF,OTCQX:FFLWF) told investors it will be entering the US market through a novel strategic action.

Meanwhile, two longstanding cannabis partners ended their relationship.

Keep reading... Show less

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less